GlassScriptPhysician profile
Kala M Garth
NPI 1124679501
$8,330.97
in general payments reported to CMS, 2019-2025
29 companies · $745 in 2025
The $745 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,199 · 2022: $2,144 · 2023: $3,097 · 2024: $1,146 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,422 · Education: $566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,422.48 |
| Education | $565.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $941.94 | 2021-2025 | |
| Incyte Corporation | $919.34 | 2021-2025 | Opzelura |
| Janssen Biotech, INC. | $751.73 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Sun Pharmaceutical Industries INC. | $730.09 | 2021-2025 | Absorica Ld, Winlevi, Ilumya |
| Genzyme Corporation | $654.62 | 2021-2024 | |
| Lilly USA, LLC | $566.20 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $544.83 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $469.17 | 2021-2025 | |
| Galderma Laboratories, L.P. | $374.37 | 2021-2025 | Nemluvio, Aklief |
| Dermavant Sciences, INC. | $246.81 | 2023-2024 | Vtama |
| Amgen INC. | $244.75 | 2021-2023 | Otezla |
| Janssen Scientific Affairs, LLC | $242.59 | 2021-2022 | |
| Pfizer INC. | $239.92 | 2021-2023 | |
| Almirall LLC | $207.54 | 2021-2025 | Klisyri, Seysara |
| Arcutis Biotherapeutics, INC. | $168.37 | 2023-2025 | Zoryve |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $163.51 | 2021-2024 | Cimzia, Bimzelx |
| Mayne Pharma Commercial LLC | $160.26 | 2021-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $139.23 | 2021-2022 | |
| Eli Lilly and Company | $99.00 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $96.72 | 2021-2023 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.58 | 2023-2024 | Spevigo |
| Leo Pharma INC. | $62.49 | 2021-2023 | Adbry |
| Genentech USA, INC. | $52.07 | 2021-2023 | Erivedge |
| Journey Medical Corporation | $47.68 | 2023 | |
| Merck Sharp & Dohme LLC | $38.57 | 2022-2023 | Keytruda |
| Sanofi-Aventis U.S. LLC | $24.97 | 2021 | |
| Merz North America, INC. | $22.19 | 2024 | |
| Verrica Pharmaceuticals INC. | $20.35 | 2024 | Ycanth |
| Organon LLC | $14.08 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kala Garth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.